0000000000051996

AUTHOR

Elena Duréndez-sáez

showing 4 related works from this author

Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers

2019

Oncologybusiness.industryCancer researchMedicineHematologybusinessMicrovesiclesAnnals of Oncology
researchProduct

An expression signature characterizes cancer stem cells from lung adenocarcinoma patients

2018

Lungmedicine.anatomical_structureOncologyCancer stem cellbusiness.industryExpression SignaturemedicineCancer researchAdenocarcinomaHematologymedicine.diseasebusinessAnnals of Oncology
researchProduct

Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer

2022

Simple Summary Non-small cell lung cancer (NSCLC) is the second most commonly diagnosed cancer and the leading cause of cancer-related death worldwide. Clinical decision-making depends on the histological classification; however, tissue biopsy is frequently not technically feasible due to tumor location or limited tissue samples. Therefore, we propose to find clinical, molecular and histological biomarkers using a minimally invasive approach based on the analysis of the cargo of the blood extracellular vesicles. Exosomes are membranous vesicles present in several biological fluids, which carry biological information to distant tissues, regulating several tumor processes. This study aims to …

squamous cell carcinomaCancer ResearchtumorspheresMICRORNASBIOMARKERSCANCER/TESTIS ANTIGENexosomesNSCLCnon-small cell lung cancer; liquid biopsy; exosomes; extracellular vesicles; cell cultures; adenocarcinoma; squamous cell carcinoma; biomarker; tumorspheresMECHANISMSRNASMICROARRAYIMMUNOTHERAPYCàncernon-small cell lung cancerScience & Technologyadenocarcinomaliquid biopsycell culturesSTATISTICSOncologyPulmonsbiomarkerextracellular vesiclesLife Sciences & Biomedicine
researchProduct

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA

2017

Lung cancer is the second most frequent tumor and the leading cause of death by cancer in both men and women. Increasing knowledge about the cancer genome and tumor environment has led to a new setting in which morphological and molecular characterization is needed to treat patients in the most personalized way in order to achieve better outcomes. Since tumor products can be detected in body fluids, the liquid biopsy, particularly, peripheral blood, has emerged as a new source for lung cancer biomarker's analysis. A variety of tumor components can be used for this purpose. Among them, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) should be especially considered. Different…

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybiologybusiness.industrynon-small cell lung cancer (NSCLC)CancerReview Articlemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineCirculating tumor cellCell-free fetal DNA030220 oncology & carcinogenesisInternal medicineImmunologymedicinebiology.proteinBiomarker (medicine)Epidermal growth factor receptorLiquid biopsyLung cancerbusiness
researchProduct